Gilotrif
| Chemical Name | afatinib |
| Dosage Form | Tablet (oral; 20mg, 30mg, and 40mg) |
| Drug Class | Kinase inhibitors |
| System | Respiratory |
| Company | Boehringer Ingelheim Pharmaceuticals |
| Approval Year | 2013 |
Indication
- For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
- For the treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy.